Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted Current Deferred Revenue of $5.1 million for Q2 2026, down 25.0% on a QoQ basis from $6.8 million in Q1 2026.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Current Deferred Revenue for 4 years, with the latest figure at $5.1 million in Q2 2026.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $5.1 million in Q2 2026; TTM through Jun 2026 was $5.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.5 million, changed N/A from the prior year.
- Current Deferred Revenue was $5.1 million for Q2 2026 at Rani Therapeutics Holdings, down from $6.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $8.5 million in Q4 2025, with the low at $600000.0 in Q3 2024.
- Average Current Deferred Revenue over 3 years is $5.3 million, with a median of $6.0 million recorded in 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.12 Mn |
| Mar 31, 2026 | 6.83 Mn |
| Dec 31, 2025 | 8.54 Mn |
| Sep 30, 2024 | 600,000.00 |
| Dec 31, 2020 | 2.72 Mn |